OncoFAP Glidotin: Canine Cancer Trial Results for a Small-Molecule Drug Conjugate

Eight client-owned pet dogs with spontaneous FAP-positive tumors participated in a dose-escalation trial of OncoFAP glidotin. Six (75%) patients responded to the therapy, with a tumor volume reduction of up to ∼88% observed in target lesions after 4 weeks. The dataset, authored by Andrea Galbiati and last updated in May 2026, contains results from this proof-of-concept study.

Use Cases

• Evaluate the safety profile of a novel small-molecule drug conjugate based on reported adverse events.
• Assess preliminary efficacy of FAP-targeted therapy based on patient response rates and tumor volume reduction.
• Compare tumor-targeting performance between antibody-drug conjugates and small-molecule conjugates as described in the study rationale.
• Plan further translational development activities for human and veterinary cancer patients based on proof-of-concept results.

Strengths

• Data originates from a clinical trial in eight client-owned dogs with spontaneous tumors, providing a relevant model for human cancer.
• The description provides specific efficacy metrics, including a 75% response rate and up to ∼88% tumor volume reduction.
• The dataset has a clear license (CC-BY-NC-4.0) and author attribution.

Limitations

• The dataset is extremely small at 1.3 KB, indicating very limited scope and likely summary-level data only.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for statistical analysis.

Provenance

Source

figshare

Collection Method

Results from a proof-of-concept dose-escalation clinical trial.

Freshness

Last updated 2026-05-16 14:07:36; freshness should be verified.